On the public citation graph

Biomarkers Associated with Immune-Related Adverse Events under Checkpoint Inhibitors in Metastatic Melanoma

https://doi.org/10.3390/cancers14020302
0 signed · 91 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1001/jamaoncol.2015.4368openalex-snapshot
Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
inferredcites →https://doi.org/10.1001/jamaoncol.2018.3923openalex-snapshot
Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors
inferredcites →https://doi.org/10.1001/jamaoncol.2019.5570openalex-snapshot
Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo
inferredcites →https://doi.org/10.1002/dmrr.2552openalex-snapshot
PD‐L1 gene polymorphisms and low serum level of PD‐L1 protein are associated to type 1 diabetes in Chile
inferredcites →https://doi.org/10.1007/s00281-018-0715-8openalex-snapshot
Sex-related factors in autoimmune liver diseases
inferredcites →https://doi.org/10.1007/s00535-018-1440-8openalex-snapshot
Clinical and pathophysiological aspects of type 1 autoimmune pancreatitis
inferredcites →https://doi.org/10.1007/s10637-019-00845-wopenalex-snapshot
Germinal Immunogenetics predict treatment outcome for PD-1/PD-L1 checkpoint inhibitors
inferredcites →https://doi.org/10.1007/s11060-019-03273-1openalex-snapshot
Neurological and related adverse events in immune checkpoint inhibitors: a pharmacovigilance study from the Japanese Adverse Drug Event Report database
inferredcites →https://doi.org/10.1007/s12026-015-8694-5openalex-snapshot
Immunological function of Blimp-1 in dendritic cells and relevance to autoimmune diseases
inferredcites →https://doi.org/10.1016/j.humpath.2017.06.012openalex-snapshot
PD-L1 and immune escape: insights from melanoma and other lineage-unrelated malignancies
inferredcites →https://doi.org/10.1016/j.jaut.2015.07.009openalex-snapshot
Immunogenetics of autoimmune thyroid diseases: A comprehensive review
inferredcites →https://doi.org/10.1016/j.jdermsci.2017.07.007openalex-snapshot
Fluctuations in routine blood count might signal severe immune-related adverse events in melanoma patients treated with nivolumab
inferredcites →https://doi.org/10.1016/j.jid.2017.06.023openalex-snapshot
HLA-A*26 Is Correlated With Response to Nivolumab in Japanese Melanoma Patients
inferredcites →https://doi.org/10.1016/s1470-2045(19)30151-2openalex-snapshot
Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial
inferredcites →https://doi.org/10.1038/leu.2016.243openalex-snapshot
Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma
inferredcites →https://doi.org/10.1038/ng.468openalex-snapshot
A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus
inferredcites →https://doi.org/10.1038/s41379-020-0499-yopenalex-snapshot
DNA copy number changes correlate with clinical behavior in melanocytic neoplasms: proposal of an algorithmic approach
inferredcites →https://doi.org/10.1038/s41591-018-0197-1openalex-snapshot
Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma
inferredcites →https://doi.org/10.1038/s41591-019-0639-4openalex-snapshot
Evolutionary divergence of HLA class I genotype impacts efficacy of cancer immunotherapy
inferredcites →https://doi.org/10.1038/s41598-019-53633-0openalex-snapshot
IL-25 exacerbates autoimmune aortitis in IL-1 receptor antagonist-deficient mice
inferredcites →https://doi.org/10.1053/j.gastro.2013.01.068openalex-snapshot
The Epidemiology of Pancreatitis and Pancreatic Cancer
inferredcites →https://doi.org/10.1056/nejmoa1504030openalex-snapshot
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
inferredcites →https://doi.org/10.1056/nejmoa1709030openalex-snapshot
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
inferredcites →https://doi.org/10.1073/pnas.1525001113openalex-snapshot
Autoimmune vitiligo is associated with gain-of-function by a transcriptional regulator that elevates expression of HLA-A*02:01 in vivo
inferredcites →https://doi.org/10.1089/thy.2016.0345openalex-snapshot
TSHR Gene Polymorphisms in the Enhancer Regions Are Most Strongly Associated with the Development of Graves’ Disease, Especially Intractable Disease, and of Hashimoto's Disease
inferredcites →https://doi.org/10.1093/annonc/mdw443openalex-snapshot
Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab
inferredcites →https://doi.org/10.1093/hmg/ddy375openalex-snapshot
FAN1 modifies Huntington’s disease progression by stabilizing the expanded HTT CAG repeat
inferredcites →https://doi.org/10.1093/jjco/hyy201openalex-snapshot
Correlation between blood cell count and outcome of melanoma patients treated with anti-PD-1 antibodies
inferredcites →https://doi.org/10.1093/rheumatology/ker211openalex-snapshot
Effects of genetic polymorphisms of programmed cell death 1 and its ligands on the development of ankylosing spondylitis
inferredcites →https://doi.org/10.1093/rheumatology/key397openalex-snapshot
Sex disparities in clinical characteristics and prognosis of immunoglobulin G4–related disease: a prospective study of 403 patients
inferredcites →https://doi.org/10.1097/cco.0000000000000709openalex-snapshot
Triplet combination of BRAF, MEK and PD-1/PD-L1 blockade in melanoma: the more the better?
inferredcites →https://doi.org/10.1111/apt.16217openalex-snapshot
Systematic review with meta‐analysis: safety and tolerability of immune checkpoint inhibitors in patients with pre‐existing inflammatory bowel diseases
inferredcites →https://doi.org/10.1111/bcpt.13284openalex-snapshot
Association between genetic polymorphisms of SLCO1B1 and susceptibility to methimazole‐induced liver injury
inferredcites →https://doi.org/10.1111/jcmm.15540openalex-snapshot
Impact of diet and genes on murine autoimmune pancreatitis
inferredcites →https://doi.org/10.1111/jgh.15041openalex-snapshot
Prevalence, clinical course, and predictive factors of immune checkpoint inhibitor monotherapy‐associated hepatitis in Japan
inferredcites →https://doi.org/10.1126/science.1258973openalex-snapshot
Mechanism of DNA interstrand cross-link processing by repair nuclease FAN1
inferredcites →https://doi.org/10.1136/esmoopen-2018-000472openalex-snapshot
Susceptible loci associated with autoimmune disease as potential biomarkers for checkpoint inhibitor-induced immune-related adverse events
inferredcites →https://doi.org/10.1158/2326-6066.cir-17-0491openalex-snapshot
Enhanced Cancer Immunotherapy with Smad3-Silenced NK-92 Cells
inferredcites →https://doi.org/10.1159/000455014openalex-snapshot
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
inferredcites →https://doi.org/10.1172/jci.insight.89569openalex-snapshot
Kruppel-like factor4 regulates PRDM1 expression through binding to an autoimmune risk allele
inferredcites →https://doi.org/10.1186/s12967-018-1467-xopenalex-snapshot
Sex and interleukin-6 are prognostic factors for autoimmune toxicity following treatment with anti-CTLA4 blockade
inferredcites →https://doi.org/10.1186/s13045-017-0433-zopenalex-snapshot
Severe nivolumab-induced pneumonitis preceding durable clinical remission in a patient with refractory, metastatic lung squamous cell cancer: a case report
inferredcites →https://doi.org/10.1186/s40425-019-0502-7openalex-snapshot
Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury
inferredcites →https://doi.org/10.1186/s40425-019-0659-0openalex-snapshot
Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma – results of a prospective biomarker study
inferredcites →https://doi.org/10.1200/jco.18.01998openalex-snapshot
Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial
inferredcites →https://doi.org/10.1200/jco.2017.73.2289openalex-snapshot
Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials
inferredcites →https://doi.org/10.1210/jc.2009-1404openalex-snapshot
Programmed Death Ligand 1 (PD-L1) Gene Variants Contribute to Autoimmune Addison’s Disease and Graves’ Disease Susceptibility
inferredcites →https://doi.org/10.1634/theoncologist.2018-0359openalex-snapshot
Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Neurologic Toxicity: Illustrative Case and Review of the Literature
inferredcites →https://doi.org/10.2174/1381612825666181219163534openalex-snapshot
Association of SLCO1B1 Polymorphisms and Atorvastatin Safety and Efficacy: A Meta-analysis
inferredcites →https://doi.org/10.2217/pgs-2016-0063openalex-snapshot
Polymorphisms in SLCO1B1 and UGT1A1 are Associated with Sorafenib-Induced Toxicity
inferredcites →https://doi.org/10.2340/00015555-2872openalex-snapshot
Blood Predictive Biomarkers for Nivolumab in Advanced Melanoma
inferredcites →https://doi.org/10.3109/08916934.2013.866101openalex-snapshot
Polymorphisms inTSHRandIL1RNgenes and the risk and prognosis of Hashimoto’s thyroiditis
inferredcites →https://doi.org/10.3390/vaccines8040616openalex-snapshot
Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma
inferredcites →https://doi.org/10.3747/co.25.4047openalex-snapshot
Predictors of Immunotherapy-Induced Immune-Related Adverse Events
inferredcites →https://doi.org/10.3892/ijo.2020.5088openalex-snapshot
Cutaneous melanoma and the immunotherapy revolution (Review)
inferredcites →https://doi.org/10.4049/jimmunol.1600941openalex-snapshot
Prdm1 Regulates Thymic Epithelial Function To Prevent Autoimmunity
inferredcites →https://doi.org/10.4110/in.2020.20.e9openalex-snapshot
Clinical Characteristics and Treatment of Immune-Related Adverse Events of Immune Checkpoint Inhibitors
inferredcites →https://doi.org/10.7326/m17-2073openalex-snapshot
Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.4775796openalex-extracted
Monocyte-Related Markers as Predictors of Immune Checkpoint Inhibitor Efficacy and Immune-Related Adverse Events: A Systematic Review and Meta-Analysis
inferred← citeshttps://doi.org/10.1007/s00262-024-03775-6openalex-snapshot
Clinical features associated with immune checkpoint inhibitor nephritis: a single-center clinical case series
inferred← citeshttps://doi.org/10.1007/s10555-025-10246-6openalex-snapshot
Monocyte-related markers as predictors of immune checkpoint inhibitor efficacy and immune-related adverse events: a systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1007/s10620-026-10120-7openalex-snapshot
Type 3 Autoimmune Pancreatitis: What Do We Know So Far?
inferred← citeshttps://doi.org/10.1007/s11886-023-01915-5openalex-snapshot
Role of Biomarkers in the Management of Immune-Checkpoint Inhibitor-Related Myocarditis
inferred← citeshttps://doi.org/10.1016/b978-0-12-823912-4.00024-4openalex-snapshot
Neurologic manifestations of autoimmunity with immune checkpoint inhibitors
inferred← citeshttps://doi.org/10.1016/j.jhepr.2025.101473openalex-snapshot
Navigating liver toxicity in the age of novel oncological agents
inferred← citeshttps://doi.org/10.1016/j.trecan.2025.07.005openalex-snapshot
Clinical perspective and treatment of immune-related colitis after cancer immunotherapy
inferred← citeshttps://doi.org/10.1038/s41571-024-00943-6openalex-snapshot
Neoadjuvant immunotherapy for dMMR and pMMR colorectal cancers: therapeutic strategies and putative biomarkers of response
inferred← citeshttps://doi.org/10.1038/s41584-022-00841-0openalex-snapshot
Immune-checkpoint inhibitor use in patients with cancer and pre-existing autoimmune diseases
inferred← citeshttps://doi.org/10.1080/1744666x.2024.2370327openalex-snapshot
Sicca syndrome/Sjögren’s disease associated with cancer immunotherapy: a narrative review on clinical presentation, biomarkers, and management
inferred← citeshttps://doi.org/10.1080/17512433.2023.2211262openalex-snapshot
Immune-related adverse events and immune checkpoint inhibitors: a focus on neurotoxicity and clinical management
inferred← citeshttps://doi.org/10.1093/jjco/hyad184openalex-snapshot
Biomarkers for immune-related adverse events in cancer patients treated with immune checkpoint inhibitors
inferred← citeshttps://doi.org/10.1097/cm9.0000000000003989openalex-snapshot
Role of LRRK2 in physiological activities, diseases, and therapy
inferred← citeshttps://doi.org/10.1097/hc9.0000000000000518openalex-snapshot
Genetic variants associated with immune-mediated liver injury from checkpoint inhibitors
inferred← citeshttps://doi.org/10.1097/mog.0000000000000873openalex-snapshot
Type 3 autoimmune pancreatitis (immune checkpoint inhibitor-induced pancreatitis)
inferred← citeshttps://doi.org/10.1097/mog.0000000000000892openalex-snapshot
Check this out: treatment paradigms in immune-checkpoint inhibitor colitis
inferred← citeshttps://doi.org/10.1111/imr.13258openalex-snapshot
Autoimmunity in immune checkpoint inhibitor‐induced immune‐related adverse events: A focus on autoimmune skin toxicity and pneumonitis
inferred← citeshttps://doi.org/10.1111/jgh.16038openalex-snapshot
Clustering using unsupervised machine learning to stratify the risk of immune‐related liver injury
inferred← citeshttps://doi.org/10.1186/s12885-025-13857-yopenalex-snapshot
Association of HLA-A*02:01 type with efficacy and toxicity of immune checkpoint inhibitor therapy in melanoma patients: a retrospective cohort study
inferred← citeshttps://doi.org/10.1248/bpb.b22-00750openalex-snapshot
Retrospective Analysis of Neutrophil-to-Lymphocyte Ratio in Patients with Melanoma Who Received Ipilimumab Monotherapy or Ipilimumab in Combination with Nivolumab in Japan
inferred← citeshttps://doi.org/10.14309/ctg.0000000000000667openalex-snapshot
Incidence of Pancreatic Injury and Pancreatitis in Patients Treated With Immune Checkpoint Inhibitors
inferred← citeshttps://doi.org/10.3389/fimmu.2026.1716934openalex-snapshot
Immune checkpoint inhibitor therapy for gastric cancer: current status, therapeutic challenges, and future prospects
inferred← citeshttps://doi.org/10.3389/fimmu.2026.1774615openalex-snapshot
Role of innate immunity in the development of cancer immunotherapy immune-mediated adverse events
inferred← citeshttps://doi.org/10.3389/fonc.2024.1287178openalex-snapshot
Risk factors for immune-related adverse effects during CPI therapy in patients with head and neck malignancies – a single center study
inferred← citeshttps://doi.org/10.3389/fonc.2026.1885789openalex-snapshot
Diagnostic research in immune checkpoint inhibitor-related pneumonitis: a bibliometric analysis of research evolution, diagnostic focuses, and future priorities
inferred← citeshttps://doi.org/10.3389/fphar.2023.1090895openalex-snapshot
Construction of a prognostic model for HCC based on ferroptosis-related lncRNAs expression and its potential to predict the response and irAEs of immunotherapy
inferred← citeshttps://doi.org/10.3390/biom15091304openalex-snapshot
A Comprehensive Oncological Biomarker Framework Guiding Precision Medicine
inferred← citeshttps://doi.org/10.3390/biomedicines13102351openalex-snapshot
Tumour SNPs Associated with Immune-Related Hepatitis in Patients with Melanoma Receiving Immune Checkpoint Inhibitors
inferred← citeshttps://doi.org/10.3390/cancers15051629openalex-snapshot
Predictive Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Events
inferred← citeshttps://doi.org/10.3390/cancers16061225openalex-snapshot
Non-Invasive Predictive Biomarkers for Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors
inferred← citeshttps://doi.org/10.3390/jpm13081210openalex-snapshot
Unveiling the Etiopathogenic Spectrum of Hypophysitis: A Narrative Review
inferred← citeshttps://doi.org/10.7150/ijbs.89376openalex-snapshot
Uncovering the flip side of immune checkpoint inhibitors: a comprehensive review of immune-related adverse events and predictive biomarkers
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.